Immuno Oncology Assays Market

Key players adopted various growth strategies such as acquisitions, product launches, agreements, partnerships, collaborations, and expansion to expand their presence in the Immuno Oncology Assays Market

The global immuno-oncology assays market size is expected to grow from USD 2.9 billion in 2018 to USD 5.9 billion by 2024, at a CAGR of 12.7% during the forecast period. Market growth is largely driven by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. On the other hand, the high cost of immunotherapy treatment and the high attrition rate in the product development cycle are expected to limit market growth.

The major immuno-oncology assay vendors include Thermo Fischer Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US). These players have adopted various growth strategies such as acquisitions, product launches, agreements, partnerships, collaborations, and expansion to expand their presence in the immuno-oncology assays market.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific holds the leading position in the immuno-oncology assays market. The company has expertise in immune-oncology research and flow cytometry. To maintain and further strengthen its position in the market, the company focuses on organic and inorganic strategies. For instance, in 2018, the company launched three assays, namely, Oncomine TCR Beta-SR Assay, Ion Torrent Oncomine Pan Cancer cell-free assay, and Torrent Oncomine tumor mutation load assay to address the challenges in this market. Moreover, in 2016, Thermo Fisher collaborated with Invivoscribe Technologies to develop NGS-based in vitro diagnostic oncology tests. The company’s extensive R&D activities help it increase the depth of capabilities in technological innovation.

Roche Diagnostics ranked second in this market. The company’s immuno-oncology assay tests are widely adopted by healthcare providers, globally. The company has majorly adopted inorganic strategies to sustain its presence in this market. Roche focuses on collaborations and acquisitions to garner a larger market share. For instance, in 2018, Roche collaborated with SQZ Biotech to develop antigen presenting cells-based immune-oncology treatments. Additionally, in 2018, Roche acquired Tusk Therapeutics to expand its oncology product portfolio.

Illumina, Inc. held the third position in the immuno-oncology assays market. The company offers advanced NGS technology platforms in the market. Illumina invests a significant amount of its revenue on R&D. In 2017, Illumina invested 19.8% of its revenue in R&D. Such significant R&D investments enable the company to develop and launch new products in the market. For instance, in 2018, the company launched its TruSight Oncology 500 assay, which is used to identify known and emerging tumor biomarkers. The company also focuses on strategic collaborations and partnerships with leading players in the market to co-develop advanced technologies and strengthen its research and commercialization capabilities.

Related Reports:

Immuno Oncology Assays Market by Product (Consumables, Software), Technology (Immunoassay, Flow Cytometry, PCR, Next Generation Sequencing), Indication (Lung Cancer, Colorectal Cancer), Application (Research, Clinical Diagnostics) - Global Forecast to 2024

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
MD 6896
Published ON
Feb, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Immuno Oncology Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved